Malabre Richard C 4

What Happened
Richard C. Malabre, Akebia Therapeutics' SVP and Chief Accounting Officer, disposed of a total of 49,524 shares on February 2, 2026 at $1.39 per share, generating aggregate proceeds of $68,838. The filings show two dispositions: 36,142 shares for $50,237 and 13,382 shares for $18,601. All transactions are reported as sales (code S).

Key Details

• Transaction date: 2026-02-02; price: $1.39 per share.
• Breakdown: 36,142 shares ($50,237) and 13,382 shares ($18,601); total 49,524 shares for $68,838.
• Shares owned after transaction: Not reported in the provided filing excerpt.
• Notable footnotes from the Form 4:
  • F1: One sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on Sept 8, 2025.
  • F2 & F3: The filing also indicates automatic issuer sales to cover tax-withholding obligations tied to the vesting/settlement of restricted stock units granted on Jan 31, 2024 and Jan 31, 2025.
• Filing date: Feb 4, 2026 — appears to be filed within the normal Form 4 reporting window (timely).

Context
A 10b5-1 plan lets insiders sell shares according to a pre-set schedule and is commonly used to avoid trading on non-public information. Automatic issuer sales to cover tax withholding when RSUs vest are routine administrative transactions and do not necessarily signal changes in insider sentiment. The total proceeds here (~$68.8k) are relatively modest.